Is Arcellx, Inc. (ACLX) a Buy, Sell, or Hold?
Arcellx, Inc.
NASDAQ:ACLX
$115.07 USD
$0.02 (0.02%)
- Volume
- 13.19M
- Average Volume
- 1.45M
- Market Capitalization
- $6.73B
- P/E Ratio
- -28.27
- Dividend Yield
- 0.00%
- Price Target
- $115.00
- Year High
- $115.13
- Year Low
- $50.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.44
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Rami Elghandour |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACLX |
| CUSIP | 03940C100 |
| CIK | 0001786205 |
| Web | https://arcellx.com |
| Phone | 240 327 0603 |
| Currency | USD |
| Employees | 163 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.24 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.44 |
| Quick Ratio | 4.44 |
| Cash Ratio | 0.77 |
Sales & Book Value
| Annual Sales | $22.29M |
| Price / Sales | 302.09 |
| Cash Flow | -3.78 |
| Price / Cash Flow | -31.67 |
| Price / Book | 16.10 |
Price Target and Rating
| Average Stock Price Forecast | $115.00 |
| High Stock Price Forecast | $120.00 |
| Low Stock Price Forecast | $82.00 |
| Forecast Upside/Downside | 0.06% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.07 |
| Trailing P/E Ratio | -28.27 |
| PEG Ratio | 0.44 |
| P/E Growth | 0.44 |
| Net Income | $-228.93M |
| Net Margin | -1027.25% |
| Pretax Margin | -1026.95% |
| Return on Equity | -55.42% |
| Return on Assets | -37.90% |
Financials Score
| AltmanZ Score | 17.98 |
| Piotroski Score | 1.00 |
| Working Capital | 357.98M |
| Total Assets | 603.99M |
| Ebit | -204.65M |
| Market Cap | 6.73B |
| Total Liabilities | 201.64M |
Poll Results
About Arcellx, Inc. (NASDAQ:ACLX) Stock
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of add ... itional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
2026-04-28 08:45:00
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
2026-04-27 10:45:59
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts
2026-04-24 02:12:49
Arcellx, Inc. (NASDAQ: ACLX - Get Free Report) has been given an average rating of "Hold" by the nineteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, sixteen have issued a hold recommendation, one has given a buy recommendation and one has given a
2026-04-17 08:30:00
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expi.
Frequently Asked Questions
-
What is the current Arcellx, Inc. (ACLX) stock price?
-
Arcellx, Inc.(NASDAQ:ACLX) stock price is $115.07 in the last trading session. During the trading session, ACLX stock reached the peak price of $115.13 while $50.85 was the lowest point it dropped to. The percentage change in ACLX stock occurred in the recent session was 0.02% while the dollar amount for the price change in ACLX stock was $0.02.
-
ACLX's industry and sector of operation?
-
The NASDAQ listed ACLX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACLX?
-
Heba Nowyhed | Chief Scientific Officer
Helen Kim | VP & Head of Regulatory Affairs
Kate Aiken | Chief People Officer
Myesha Lacy | Chief Investor & Communications Officer
Narinderjeet Singh | Chief Technical Officer -
How many employees does ACLX have?
-
Number of ACLX employees currently stands at 163. ACLX operates from 25 West Watkins Mill Road, Redwood City, MD 20878, US.
-
Link for ACLX official website?
-
Official Website of ACLX is: https://arcellx.com
-
How do I contact ACLX?
-
ACLX could be contacted at phone #240 327 0603 and can also be accessed through its website. ACLX operates from 25 West Watkins Mill Road, Redwood City, MD 20878, US.
-
How many shares of ACLX are traded daily?
-
The average number of ACLX shares traded daily for last 3 months was 1.45M.
-
What is the market cap of ACLX currently?
-
The market value of ACLX currently stands at $6.73B with its latest stock price at $115.07